1.	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCNONCO200801, NCT00777504
2.	Biological, Pathological and Imagery Markers in the First-Line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070104, NCT00930345
3.	An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
4.	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: SG 327/10, NCT01402089
5.	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
6.	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and ove Sponsor: Other Protocol IDs: iOM-605, 2011-001138-40, NCT01521715
7.	SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889
8.	A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181109, NCT00375674
9.	Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
10.	Trial of Collagen Mesh for Prevention of Ventral Hernia After Surgery for Advanced Pelvic Cancer Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: VRAM M-20070240, NCT00647569
11.	Clinical Trial to Assess the Importance of Nephrectomy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P070144, NCT00930033
12.	Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000668388, SWOG-S0931, S0931, NCT01120249
13.	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-30073, EU-21022, PFIZER-EORTC-30073, NCT01099423
14.	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90802, CALGB-90802, NCT01198158
15.	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CTKI258A2302, 2009-015459-25, NCT01223027
16.	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113387, NCT01235962
17.	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: CROSS-J-RCC, UMIN000003040, NCT01481870
18.	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E2810, E2810, NCT01575548
19.	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AGS-003-007, 2012-000871-17, NCT01582672
20.	Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AP311736, NCT01599754
21.	Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846
22.	Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-025, 2011-005132-26, NCT01668784
23.	A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation Phase: Phase III Type: Treatment Status: Active Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: E7040-J081-301, NCT01677624
24.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
25.	Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 4K-05-1, NCT00184015